Department of Radiation oncology and experimental cancer research (ceased 1-10-2018)

The extracellular RNA quality control (exRNAQC) study : controlling pre-analytical variables of RNA sequencing in blood-based precision medicine

Francisco Avila Cobos (UGent) , Anneleen Decock (UGent) , Katleen De Preter (UGent) , Bert Dhondt (UGent) , Olivier De Wever (UGent) , Bram De Wilde (UGent) , Celine Everaert (UGent) , Carolina Fierro, Hetty Helsmoortel (UGent) , An Hendrix (UGent) , et al.

(2018) Research Day & Student Research Symposium.

Add to list

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer

Bram De Laere, Steffi Oeyen, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, et al.

(2018) PROSTATE. 78(6). p.435-445

Add to list

Journal Article
A1
open access

Stereotactic body radiotherapy for primary prostate cancer

Gargi Kothari, Andrew Loblaw, Alison C. Tree, Nicholas J. van As, Drew Moghanaki, Simon S. Lo, Piet Ost (UGent) and Shankar Siva

(2018) TECHNOLOGY IN CANCER RESEARCH & TREATMENT. 17.

Add to list

How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator

Giorgio Gandaglia, Roderick C. N. van den Bergh, Derya Tilki, Nicola Fossati, Piet Ost (UGent) , Christian I. Surcel, Prasanna Sooriakumaran, Igor Tsaur, Massimo Valerio, Alexander Kretschmer, et al.

(2018) BJU INTERNATIONAL. 122(5). p.823-830

Add to list

Combining anticancer drugs with osteoprotective agents in prostate cancer : a contemporary update

Igor Tsaur, Isabel Heidegger, Alexander Kretschmer, Hendrik Borgmann, Cristian Mirvald, Giorgio Gandaglia, Alberto Briganti, Roderick van den Bergh, Derya Tilki, Piet Ost (UGent) , et al.

(2018) UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 36(11). p.488-497

Add to list

Journal Article
A1
open access

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Markus Mayrhofer, Bram De Laere, Tom Whitington, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, Lucien Hoekx, Dirk Schrijvers, et al.

(2018) GENOME MEDICINE. 10.

Add to list

Consensus on molecular imaging and theranostics in prostate cancer

Stefano Fanti, Silvia Minozzi, Gerald Antoch, Ian Banks, Alberto Briganti, Ignasi Carrio, Arturo Chiti, Noel Clarke, Matthias Eiber, Johann De Bono, et al.

(2018) LANCET ONCOLOGY. 19(12). p.E696-E708

Add to list

AR-V7 predicting treatment response in metastasized prostate cancer : has it peaked?

Igor Tsaur, Hendrik Borgmann, Christian I. Surcel, Piet Ost (UGent) and Guillaume Ploussard

(2018) WORLD JOURNAL OF UROLOGY. 36(1). p.149-151

Add to list

Journal Article
A1
open access

Prostate cancer-specific PET radiotracers : a review on the clinical utility in recurrent disease

Jaden D. Evans, Krishan R. Jethwa, Piet Ost (UGent) , Scott Williams, Eugene D. Kwon, Val J. Lowe and Brian J. Davis

(2018) PRACTICAL RADIATION ONCOLOGY. 8(1). p.28-39

Add to list

Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy

Nicola Fossati, R. Jeffrey Karnes, Michele Colicchia, Stephen A. Boorjian, Alberto Bossi, Thomas Seisen, Nadia Di Muzio, Cesare Cozzarini, Barbara Noris Chiorda, Claudio Fiorino, et al.

(2018) EUROPEAN UROLOGY. 73(3). p.436-444

Academic Bibliography

Department of Radiation oncology and experimental cancer research (ceased 1-10-2018)

The extracellular RNA quality control (exRNAQC) study : controlling pre-analytical variables of RNA sequencing in blood-based precision medicine

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer

Stereotactic body radiotherapy for primary prostate cancer

How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator

Combining anticancer drugs with osteoprotective agents in prostate cancer : a contemporary update

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Consensus on molecular imaging and theranostics in prostate cancer

AR-V7 predicting treatment response in metastasized prostate cancer : has it peaked?

Prostate cancer-specific PET radiotracers : a review on the clinical utility in recurrent disease

Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy

Contents

Support

Contact